美国65岁及以上Medicare受益人接种两种RSV疫苗后健康结局的安全性监测(2023-2024)
本研究利用美国Medicare行政索赔数据,采用自身对照病例系列设计,评估65岁及以上人群接种RSVPreF3+AS01和RSVPreF两种RSV疫苗后11种预设健康结局的风险。
要点
- 两种RSV疫苗在65岁及以上Medicare受益人中未显示预设健康结局风险显著升高。
- 调整后IRR范围0.54至5.99,调整后AR范围-22.57至0.77例/10万剂,均无统计学显著性。
- 吉兰-巴雷综合征评估已另行报告,不在本研究范围内。
核心结论
- 研究结果提示接种RSV疫苗后这些预设健康结局风险未增加,支持对65岁及以上美国成人接种RSV疫苗的监管决策。
研究设计与样本
- 自身对照病例系列研究,使用2023年5月3日至2024年7月13日Medicare行政索赔数据,比较11种预设健康结局在接种后风险间期与对照间期的发生率。
- 采用条件Poisson回归估计发病率比(IRR)及99%置信区间(CI),并估算每10万剂疫苗的归因风险(AR)及99%CI,分析中调整季节性和事件依赖性观察时间。
主要发现
- 接种RSV疫苗后所评估的预设健康结局均未观察到统计学显著的风险升高。
- 调整后IRR均无统计学显著性,范围从0.54(99%CI:0.16,1.76,RSVPreF,脑脊髓炎除外急性播散性脑脊髓炎)到5.99(99%CI:0.34,106.47,RSVPreF3+AS01,过敏反应)。
- 调整后AR均无统计学显著性,范围从-22.57例/10万剂(99%CI:-47.38,2.23,RSVPreF,心房颤动)到0.77例/10万剂(99%CI:-1.77,3.32,RSVPreF3+AS01,1-21天风险间期非出血性卒中)。
临床怎么用
- 为65岁及以上成人接种RSV疫苗的安全性监测提供数据支持,未发现预设健康结局风险显著升高。
- 接种决策可参考本研究结果,但吉兰-巴雷综合征评估需参阅另行报告。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The United States Food and Drug Administration (FDA) conducts post-market surveillance to monitor the safety of vaccines and evaluate potential health outcomes not identified in prelicensure clinical trials or through passive surveillance systems. We evaluated the risk of prespecified health outcomes following two Respiratory Syncytial Virus (RSV) vaccines- GlaxoSmithKline AREXVY ® (RSVPreF3 + AS01) and Pfizer ABRYSVO ® (RSVPreF)-among Medicare beneficiaries aged ≥65 years. Evaluation of Guillain-Barré syndrome following RSV vaccination was reported separately. METHODS: This self-controlled case series study compared the incidence of 11 prespecified health outcomes using Medicare administrative claims data during May 3, 2023 - July 13, 2024. Using conditional Poisson regression, incidence rate ratios (IRR) with 99% confidence intervals (CIs) were estimated to compare outcome rates between post-vaccination risk and control intervals for each vaccine separately; analyses were adjusted for seasonality and event-dependent observation time, where appropriate. Attributable risk (AR) and 99% CIs estimated the excess number of outcomes per 100,000 vaccine doses. RESULTS: Approximately 3.82 million beneficiaries received an RSV vaccination during the study period (RSVPreF3 + AS01: 2.60 million; RSVPreF: 1.21 million). No statistically significant elevation in risk was observed for the prespecified health outcomes examined following RSV vaccination. Adjusted IRRs were not statistically significant and ranged from 0.54 (99% CI: 0.16, 1.76) for encephalomyelitis excluding acute disseminated encephalomyelitis (RSVPreF) to 5.99 (99% CI: 0.34, 106.47) for anaphylaxis (RSVPreF3 + AS01). Similarly, adjusted ARs were not statistically significant and ranged from -22.57 excess cases per 100,000 vaccine doses (99% CI: -47.38, 2.23) for atrial fibrillation (RSVPreF) to 0.77 (99% CI: -1.77, 3.32) for non-hemorrhagic stroke in 1-21-day risk interval (RSVPreF3 + AS01). CONCLUSION: Findings from this study suggest no increased risk of these health outcomes following RSV vaccination. These results contribute to the larger U.S. federal government vaccine safety monitoring efforts and further supports regulatory decision-making regarding RSV vaccines administered to U.S. adults aged 65 years and older.
引用
- Lloyd PC, Shah PB, Zhang HT, et al. Safety monitoring of health outcomes following RSVPreF3 + AS01 and RSVPreF vaccination among Medicare beneficiaries aged 65 years and older in the United States, 2023-2024. Vaccine. 2026. PMID: 41833132. doi:10.1016/j.vaccine.2026.128459
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。